

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE SUBOXONE (BUPRENORPHINE
HYDROCHLORIDE AND NALOXONE)
ANTITRUST LITIGATION**

**MDL NO. 2445
13-MD-2445**

THIS DOCUMENT RELATES TO:

Wisconsin, et al. v. Indivior Inc. et al.
Case No. 16-cv-5073

STATE OF WISCONSIN

By Attorney General Brad D. Schimel, et al.

CIV. A. NO. 16-5073

Plaintiffs,

v.

**INDIVIOR INC. f/k/a RECKITT BENCKISER
PHARMACEUTICALS, INC., et al.**

Defendants.

ORDER

AND NOW, this 16th day of October, 2017, upon consideration of Defendant Reckitt Benckiser Healthcare (UK) Ltd.'s Motion to Dismiss (16-cv-5073, Doc. No. 141), Plaintiffs' Response in Opposition (16-cv-5073, Doc. No. 164), and Reckitt Benckiser Healthcare (UK) Ltd's Reply Brief (16-cv-5073, Doc. No. 174), it is hereby **ORDERED** that the Motion is **GRANTED** and all claims against Defendant Reckitt Benckiser Healthcare (UK) Ltd. are **DISMISSED**.

BY THE COURT:

/s/ Mitchell S. Goldberg

MITCHELL S. GOLDBERG, J.